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Aim: To raise awareness on nocturia disease burden and to provide simplified aetio-
logic evaluation and related treatment pathways.
Methods:Amultidisciplinarygroupofnocturiaexpertsdevelopedpracticaladviceand








ismultifactorialandtypically relatedtopolyuria (eitherglobalornocturnal), reduced




patients with sustained bother, medical therapies should be introduced; low- dose, 
gender- specific desmopressin has proven effective in nocturia due to idiopathic noctur-
nal polyuria. The timing of diuretics is an important consideration, and they should be 
takenmid-lateafternoon,dependentonthespecificserumhalf-life.Patientsnot re-
sponding to these basic treatments should be referred for specialist management.





finedby the InternationalContinenceSociety (ICS) as “the complaint
that the individualhas towakeatnightoneormore times tovoid…
each void is preceded and followed by sleep.”1,2Nocturiaequallyaffects
men and women of all ages, with higher rates in older populations.3-5 It is 
associated with falls and fall- related injuries, primarily in the elderly but 
alsoinyoungeragegroups,reducedqualityoflife(QoL),mainlydueto
fragmented sleep, and an increased prevalence of depressive symptoms, 
particularly in younger men and women.5-13 Nocturia also places a con-
siderable economic burden on the individual and healthcare services, in 
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treated and poorly managed medical and social problem in adults.15,16 
Nocturia was oftentimes considered a symptom associated with func-
tional issues, suchasoveractivebladdersyndrome (OAB)and/orbe-
nignprostatichyperplasia(BPH),withtreatmentsfocusedonincreasing
bladder capacity and/or lowering bladder outlet obstruction. However, 
because nocturia is often associated with nocturnal polyuria—the over-
production of urine during the night—such treatments will not be effec-
tive for all patients and appropriate patient selection is essential.17-19As
such, it is essential that physicians and other healthcare professionals 
understand the aetiology, burden and the most effective methods for 
diagnosing, assessing and treating nocturia. The treatment of nocturia 
should be according to its causative factors and aetiology where possi-
ble,asrecommendedintheEuropeanAssociationofUrologyguidelines
onthetreatmentofmaleLUTS20; however, specific guidelines for noc-
turia have not yet been published as a journal article.
1.1 | Aim
Theaimofthisexpertpaperwastoraiseawarenessandincreaserec-
ognition of nocturia as a medical condition and provide straightfor-
ward, practical recommendations for its diagnosis and management.
2  | METHODS
Thepaperwasdevelopedbyamultidisciplinarygroupofexpertson
nocturia, including urologists, general practitioners and a geriatrician 
with a special interest in nocturia. A non-systematic review of the




thors intend that the recommendations and practical advice provided 
herein will improve confidence in the management of nocturia and 
help define when specialist referral is appropriate.
3  | RESULTS AND DISCUSSION
3.1 | Terminology
In2002,theICSdefinednocturiaasthe need to void one or more times 
during the night, with each void preceded and followed by sleep.1,2 This 
definition is currently a topic of debate21,22; however, nocturia often 
only becomes clinically relevant when it causes comorbidities or 
bother for the patient. Nocturia once per night has been reported to 
occur inupto18.2%ofhealthywomenaged18-30years,butwith
low associated bother to the individual.23Amoreclinically relevant
definitionofnocturiais“≥2voidspernight,”asatthispointitwould
become bothersome for most individuals.13,24 It should be recognised, 
however, that perceptions of what frequency is bothersome may





Nocturia is one of the most bothersome LUTS according to most
epidemiological studies.7,25,26 The prevalence of nocturia is high and 
broadlysimilarinmenandwomen,affecting28%-93%ofthoseaged






lence of nocturia in the community increases with age, with rates of 
29%-59%formenaged70-80yearsandof28%-62%forwomenof
thesameage(≥2voidspernight).27 Other studies have reported rates 
of16%inmenand21%inwomenagedover20years(≥2voidsper
night),29and34%formenand28%forwomen(>2voidspernight)
aged over 40 years.28Inanotherstudy,reportingaprevalenceof34%
inwomenaged>40years,itwasfoundthat40%ofthosewithnoc-
turia had no other urinary tract symptom.26




3.3 | Evaluating patients with nocturia
Numerous underlying factors may contribute to nocturia, and one or 





evidence combined with practical insights from the authors’ 
extensiveexperiencesinmanagingpatientswithnocturia.
What’s new
•  Nocturia is a bothersome and serious medical condition 
affecting men and women of all ages, which can nega-
tively impact quality of life and increasemorbidity and
mortality.Frequency-volumechartsareessentialforac-
curate assessment. Treatment should be tailored to the 
individual patient based on the underlying pathophysiol-
ogy, with lifestyle interventions always considered. 
Medical therapies, such as desmopressin in patients with 
idiopathic nocturnal polyuria, can provide effective and 
safe relief for patients with persistent bother.
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polyuriaisveryfrequentlyassociatedwithaLUTS/BPHinmenoran
OABinwomen).18 The multifactorial pathophysiology of nocturia may 
partlyexplainwhyithasnotreceivedappropriateattentionasadis-
tinct medical presentation.19,31 The pathophysiological mechanisms for 
nocturiacanbebroadlyseparatedintothreemaincauses:(i)reduced
bladdercapacity, (ii) increasedfluidintakeand(iii) increaseddiuresis,
with certain medications and behavioural factors exacerbating the
condition(Figure1).18,19,28,31-34 It has been observed that patients with 
≥2voidspernighthavehighernocturnalvoidedvolume,basedonin-
creasedsodiumexcretionandlowerfunctionalbladdercapacity,whilst
those with 1 void per night present with lower bladder capacity.35 The 
possible pathophysiological factors involved in nocturia in men and 
womenarebroadlysimilar,withtheexceptionofprostate-relatedis-
sues in men and oestrogen deficiency in women, the latter with an 
uncertain but possible marginal role in the development of nocturia.36
3.3.1 | Reduced (nocturnal) bladder capacity
Reduced bladder capacity, whether functional or anatomic, encom-
passes all the conditions associated with storage dysfunction and 
storagesymptoms.Nocturiaoccurswhenthebladdercapacityisex-
ceeded by the amount of urine entering the bladder during the night.33 
Reduced bladder capacity may indicate detrusor overactivity (primary 
[idiopathic]orsecondary,eg,duetoneurogenicbladderdysfunction),
overactive bladder without detrusor overactivity, postvoid residual 
urine due to bladder outlet obstruction, chronic pelvic/bladder pain 





either throughout the 24- hour period or specifically in the evening/
night.32Fluidintakeintheeveningornightcanoftenhavebehavioural
andlifestylecauses,andsuchintakeisalsooftenassociatedwiththe
consumption of diuretic beverages (such as caffeine or alcohol).18 
Excessfluidintakecanalsohaveanumberofothercausesincluding







caemia or primary polydipsia, or it can be drug- induced.33
F IGURE  1 Pathophysiologyofnocturia(adaptedfromOelkeetal32)
24 h Evening/night 24 h Night
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sible forup to88%of cases.2,38,39 Nocturnal polyuria is thought to 
result from an abnormality of the circadian rhythm of secretion of the 
antidiuretichormone,argininevasopressin(AVP).Itisaheterogene-
ous condition, in which water diuresis, solute diuresis or a combina-
tion of both is the underlying cause.40 Water diuresis is represented 
byhighfreewaterclearanceandlowosmolalityatnight.Forsolute





sleep apnoea (OSA), renal tubular dysfunction, hepatic failure and
hypoalbuminaemiacancausefluidandelectrolytesequestrationand,
therefore, may also be reasons for nocturnal polyuria.31,33,41
3.4 | Risk factors and comorbidities
Nocturia (≥2voidspernight)hasbeen significantly associatedwith
various risk factorsandcomorbidities (Table1).28Severalepidemio-
logical studies have also reported a positive association between noc-
turia and erectile dysfunction in diabetic42 and non- diabetic men.43
3.5 | Impact of nocturia
Nocturiacanhaveasignificant,negative impactonpatients’QoL
(both mental and physical) and be linked to depression and in-
creased mortality.5,6,9,13,29TheimpactonQoLcomesprimarilyfrom
disturbed sleep caused by nocturia, which can lead to sleep depri-
vation, especially when there is difficulty in returning to sleep.5,10 
This leads to tiredness and daytime fatigue that can affect daily 
activitiesandtherebyreduceQoL.5,10 Nocturnal voiding can nega-
tively affect the occurrence and length of deep, restorative (N3)
sleep, often considered the most restorative stage of sleep.44 Long- 
term loss of N3 sleep as occurs in nocturia could have potentially 
deleterious impact on daytime alertness, health and well- being.44,45 
The negative effect of nocturia on sleep outcomes appears to be 
stronger in adults aged >65 years.46Asnocturiacausesactivityat
nightwhenapatientmaynotbefullyawake,itisalsoanimportant
cause of falls and fall- related fractures in the elderly population.5,8 
Apopulation-basedepidemiologic survey also found a strong as-
sociation of nocturia with depression in both men and women, with 
a significant trend in increased odds of depression with more voids 
nightly.13 The magnitude of this association was larger in younger 
age groups, especially among women aged <50 years.13 Nocturia 
(≥2voidspernight)hasbeenfoundtoincreasethemortalityriskby
54% inmen (hazardratio [HR]1.54,95%confidence interval [CI]
1.18-2.00)andby28% inwomen (HR1.28,95%CI1.04-1.57).29 
Interestingly, the magnitude of the association was greater in 
men and women <65 years. There was a significant trend for in-
creasedmortality riskwith increasing number of nocturnal void-
ing episodes. Potential underlying mechanisms for this association 
includedsleepdisruptionandsubsequentdevelopmentofrelated
comorbid conditions.29
An increasing numberof epidemiological studies have shown a
strong association between sleep deprivation and adverse metabolic 
traits, including obesity, type 2 diabetes and arterial hypertension, 
with experimental evidence suggesting distinct pathophysiological
mechanisms by which insufficient sleep impairs metabolic health.47 
Eachof thesemetabolicdiseases is likely tobe associatedwith an
increasedrisk forprematuredeath.47Ameta-analysisof16studies
involving 1 382 999 people reported <7 hours of sleep to be asso-
ciatedwithanincreasedriskofall-causemortality(relativerisk[RR]
1.12,95%CI1.06-1.18;P<.01),although>8hoursofsleepwasalso
associatedwith an increased risk of death (RR1.30, 95%CI 1.22-
1.38; P>.0001), perhaps due to socio-economic factors and/or
comorbidities.48
The impact of nocturia has considerable pecuniary implications for 
patients and the health service. It was estimated that hospitalisations 
acrosstheEUduetohipfracturesassociatedwithnocturiacostap-
proximately€1.0billionin2014.5 In addition to these direct costs, in-
directcostsarisefromdecreasedworkproductivityandactivitylevels,
withlostproductivityatworkintheEUregionin2014duetonocturia
estimated to have cost €29.0 billion.5 In theUSA, theannualdirect
costsdue tonocturia-associated fallswereestimated tobeapprox-
imately$1.5billionandthe indirectcostswereexpectedtobe$61
billion in 2014.5
3.6 | Clinical presentation and evaluation
Many patients may not recognise nocturia as a medical condition ame-
nable to treatment or they may be embarrassed or reluctant to discuss 
symptoms,15,49,50 so there is an onus on the physician to broach the 













• High blood pressure
• Anxiety
• Depression















aGenerally considered to be associated with overall urogenital prolapse or 
pelvic floor dysfunction.
     |  5 of 11OELKE Et aL.
which prevented them from seeking treatment.15 Of those women 
whohadconsultedadoctor,37.2%werenotofferedanytreatment.15 




treatment.16 The overall time from the onset of symptoms to begin-
ningtreatmentwasnearly2years(mean105.5weeks).16 In this study, 
themostcommonreasonforseekingmedicalhelpwasworseningof
symptoms (severity or frequency). Urinary incontinence, tiredness,
fearofother(serious)underlyingdiseasesandrecommendationofa
friend or relative were other important reasons to consult a doctor.16 
This study implied that there should be greater awareness and screen-
ing for nocturia, even in the absence of other urinary symptoms.
Athoroughassessmentofnocturiaanditspossiblecausesiscru-
cialbeforetreatmentinitiation(Table2;alsoseeChecklistavailableas
onlinematerial).32,52-54 The evaluation of a patient should begin with 
takingathoroughhistorytoassess,understandanddiscriminateLUTS
in general and nocturia in particular.
Frequency-volume charts (FVCs) are the cornerstone of ini-
tial assessment and are pivotal in determining the type of nocturia 
and associated causes (Figure2)32 (example available as onlinema-
terial; see also www.opstaanomteplassen.be and Everaert etal56).




between the major causes of nocturia, can identify the underlying 
pathophysiology and can determine the sleep pattern of the patient.32 
Analysisofpatients’FVCswillrevealmanyimportantcluestotheaeti-




aetiologies.33 Use of a screening tool, such as the recently published 
TANGO(Targetingtheindividual’sAetiologytoGuideOutcomes),57,58 
can also potentially aid in the identification and assessment of non- 
lowerurinarytractcomorbiditiesassociatedwithnocturia.FVCscan
be supplemented by bladder diaries, which are especially useful in 
compliant patients over longer stretches of time and provide an op-
portunity for patients to add important qualitative details about or
associated with their symptoms.59FVCsorbladderdiariesshouldbe
completed for a minimum of 3 days, and it is important that the need 
foraccuracyisexplainedtothepatientbeforeaskingthemtocom-




Treatment should be tailored to the underlying causes of noc-
turia (Figure1) and should include lifestyle modifications and, if
required,pharmacological therapy (Figure3).32Somemedications
can precipitate nocturia and, therefore, a medication review is 
warranted in all patients (see lifestylemodifications, below). It is
Recommendations on the assessment of nocturia





of postvoid residual volume should be performed in all cases 
and followed up with additional tests (eg, uroflowmetry, 
computer-urodynamic evaluation of bladder function and 
cystoscopy,etc)aswarranted.
• Diagnosis of nocturia and nocturnal polyuria should be based 
ontheresultsofaFVCandsubsequentinvestigationstodis-
criminate among the potential underlying causes of nocturia 
(Figure1).
• FVCsmaybesupplementedbybladderdiaries.
• The patient should be referred to the relevant specialty 






habits, medical history, symptoms of obstructive sleep apnoea 
(considerusingtheEpworthSleepinessScaleorSTOP-BANG54)
























raphy, magnetic resonance imaging of the chest or coronary 
angiography)
○ MeasurementofPVRasevaluatedbytransabdominalultra-
sonography, a bladder scan or catheterisation 
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important that patients are informed about the goals of treatment: 




Pharmacological therapies are indicated after failure of lifestyle modi-
fications and behavioural treatments which, however, should be con-
tinued together with the drugs. Several pharmacological therapies
have been used for the treatment of nocturia, depending on the un-
derlyingcause(s),including32 antidiuretic agents (vasopressin receptor 
agonists; desmopressin), diuretics, muscarinic receptor antagonists
(antimuscarinics), β3-adrenoceptor agonists (mirabegron),
66 alpha- 
adrenoceptor antagonists (α1-blockers),5α- reductase inhibitors, phos-
phodiesterase type 5 inhibitors (PDE5i) and plant extracts. Except
for desmopressin in the treatment of patients with nocturia due to 
nocturnal polyuria,67-70 the strength of evidence for many of these 
agents has been classified as low by the International Consultations 
on Urological Diseases committee.37,71
Reduced (nocturnal) bladder capacity
The use of antimuscarinics or β3-agonists(mirabegron)foroveractive
bladder management and α1-blockers,5α- reductase inhibitors with or 
without α1-blockers,PDE5iorplantextractsformaleLUTS/bladder
outlet obstruction has been shown to significantly reduce nocturnal 




injections in reducing night- time nocturia in patients with overactive 
bladder without nocturnal polyuria.75-77
Increased diuresis
Desmopressin, a syntheticvasopressinanalogue,actson theV2 re-
ceptors of the distal collecting tubules with the aim of concentrating 
urine at night.33TreatmentwithaV2 agonist is useful only in patients 
with idiopathic nocturnal polyuriawith excessivewater diuresis, or
in patients with central diabetes insipidus, as this is indicative of 
suppressed vasopressin levels.40 However, where there is noctur-
nal sodium diuresis, treatment to restore a normal sodium clearance 
F IGURE  2 Nocturiaevaluationalgorithmbasedonfrequency-volumechart(adaptedfromOelkeetal32).*Somepatientsmightnotrequire
referraltoacardiologist.TheNationalInstituteforHealthandCareExcellence(NICE)guidelinesforchronicheartfailurestatethatreferralof
patients to a cardiologist is only necessary for initial diagnosis and patients with severe heart failure or where the condition is not responding to 
treatment62
Frequency volume chart
Reduced maximum voided 
volume, urinary frequency
24-h or evening polydipsia 24-h urine volume, 
>40 mL/kg bodyweight
Nocturnal urine volume, >20% 
(young)/33% (elderly) of 24-h 
urine volume
Reduced bladder capacity Increased fluid intake Global polyuria Nocturnal polyuria
Consider primary or secondary 
bladder/prostate disorders:
- Urinalysis
- Postvoid residual 




Consider the amount and type 
of fluids and the mes of 
drinking:
- Diabetes insipidus and 
diabetes mellitus in rela
on to 
polydipsia caused by polyuria
Consider the following:
Type 1 or Type 2 diabetes 
mellitus
- Blood/urine glucose level
Diabetes insipidus 
Primary polydipsia
Oestrogen level in women
Serum Ca2+
Consider the following:
Impaired circadian rhythm of 
arginine vasopressin (AVP) 
secreon
Congesve heart failure
- Refer to cardiologist*
Sleep apnoea
- Refer to sleep specialist
Prescripon drugs affecng AVP 
secreon 
- e.g. lithium or tetracyclines
- Diure
cs
Peripheral oedema in paents 
with venous insufficiency 
(varicosis) of lower extremies 
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pattern could be indicated as this would act to lower nocturnal urine 
production.40
Desmopressin has shown to be an efficacious and well- tolerated 
treatment for patients with nocturia due to nocturnal polyuria, with 
femalesrequiringlowereffectivedosescomparedtomales.67-70 Nasal 
spray, oral tablet and sublingual melt formulations of desmopressin 
have been developed, although not all formulations and doses are 
availableineverycountry.Eachofthesehasspecificpharmacological
properties and doses. For example, the sublingualmelt formulation
hasatimetomaximumplasmaconcentrationof0.5-2.0hoursanda
serum half- life of around 2.8 hours, meaning that its effect lasts for ap-
proximately8hours.78Aonce-daily,low-dose,gender-specificformu-
lation of desmopressin has lately become available: 25 μg for women 
and 50 μg for men.79 This formulation has the benefit of reducing the 
antidiuretic activity to a maximum of 3-5hours during the nightly
sleep,79 whilst also limiting the risk of hyponatraemia, an adverse




dosing; otherwise, fluid retention and/or hyponatraemia may result.79
Comparison of 25 μg desmopressin once daily to placebo in 261 
womenwithnocturia(≥2voidspernight)foundthatdesmopressinsig-
nificantly reduced the mean number of nocturnal voids and increased the 
mean time to first nocturnal void by 49 minutes compared with placebo 
at 3 months.67Similarefficacyhasbeendemonstrated inastudythat
investigated 50 and 75 μgdesmopressininmenwithnocturia(≥2voids
pernight).68Significantincreasesinhealth-relatedQoLandundisturbed
sleep were also observed compared with placebo.45,68Afurtherstudy
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• Reduce fluid intake if 
no diabetes mellitus 
or diabetes insipidus
• Consult psychiatrist 
in case of 
psychogenic 
polydipsia
Wrong me of fluid 
intake
• Change me of fluid 




• Treat diabetes 
mellitus  (I/II)
• Treat diabetes  
insipidus




• Replace fluid intake 
in paents with 
polydipsia
Nocturnal polyuria
• Arginine vasopressin 
(AVP) analogue 
(vasopressin) in 
paents with low 
nocturnal levels  of 
AVP
• Treat cardiac 
insufficiency (refer 
cardiologist)
• Treat sleep apnoea 
(refer 
pulmonologist)
• Change me of 
diurec use from 
evening to morning 
or midday
• Treat chronic venous 
insufficiency of the 
lower extremies 











• Weight loss if overweight/obese
• Forpatientswithperipheraloedema(lowerextremities)dueto
congestive heart failure or chronic venous insufficiency
○ Elevatingthelegsabovetheheartlevelafewhoursbeforegoing




diuretic (eg, furosemide has a serum half-life of ~1.5 hours and 
torasemide~3.5hours)
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tobemoresensitive to thismedicationandtherefore requirea lower
dose (25 μg vs 50 μginmen)toachieveclinicalimprovement.69Apooled
analysis of three randomised, controlled trials reported that these effects 
can be maintained and even enhanced over the course of a year.70
Hyponatraemia after desmopressin intake, defined as a serum
sodium concentration <130 mmol/L but not necessarily associated 
withsymptomsorsigns,occurs in5.0%-7.6%of individualsandhas
mostfrequentlybeenobservedinpatients>65yearsofage,especially
in women, and individuals with low serum sodium concentration at 
baseline and higher 24- hour urine volume per body weight.80,81For
older patients, serum sodium monitoring before starting treatment 
and in the early phase of treatment (after 4- 8 days and at 1 month 
afterinitiation)canhelptoquicklyidentifyhyponatraemicpatients.72 
Educationofpatientsandtheirpartnersonrecognisinghyponatraemia
shouldalsobeundertakentoensurerapid identification if itoccurs.
Symptoms or signs of hyponatraemia—usually associated with the
degree of decreased serum sodium level—start with nausea, vomit-
ing, headache and lethargy. In rare cases, confusion, decreased con-
sciousnessandmuscleweakness,spasmsorcramps,andseizuresor
coma can occur. Relevant factors that could affect the sodium level in 
patients includegender, lowbaselineserumsodium,reducedkidney
function, cardiac or renal comorbidity, polypharmacy with diuretics80 
andinjudiciousliquidintake.
In contrast to the antidiuretic drug desmopressin, the aim of di-
uretics for nocturia is to induce diuresis before sleep and to shift the 
polyuric phase from night-time (sleep) to daytime.31 This approach 
may be suitable for patients with nocturia when the underlying cause 
isunknown,59 although the overall evidence supporting the use of di-
uretic therapy is low. Timing of diuretic therapy is important. Patients 
with nocturnal polyuria as a result of fluid reabsorption in the lower 
extremitieswhilst lyingdownshouldtaketheirdiuretics inthemid-
afternoontoreleasefluidbuiltupduringtheday;iftakentoolatein
the day, it may inadvertently increase nocturnal polyuria.72
Combined therapy
In cases with a multifactorial aetiology of nocturia, treatment could 
target the various underlying causes with two or more drugs and, if 
necessary, in a multidisciplinary setting, but should always involve 
lifestyle changes and behavioural therapies. The addition of low- dose 
oral desmopressin 50 μg to the α1-blocker tamsulosinhasshownto
reduce the nocturnal frequency of voids by 64.3% compared with
44.6% when tamsulosin was given alone in patients with signs or
symptomsofBPH(withorwithoutnocturnalpolyuria).82 The study 
alsodemonstratedthatthiscombinationtherapyimprovedthequal-
ity of sleep, whilst overall tolerability remained comparable to tamsu-
losin monotherapy.82Similarresultshavebeenseenwhenlow-dose
desmopressin was added to other α1-blockers formenwith LUTS/
BPH.83,84 A recently published, double-blind, randomised, proof-of-
concept study showed that a combination of desmopressin 25 μg and 
the antimuscarinic tolterodine provided a significant benefit in noctur-
nal void volume (P=.034)andtimetofirstnocturnalvoid(P=.045)
over tolterodine monotherapy in women with OAB and nocturnal
polyuria.85
3.7.2 | Other interventions
Surgical procedures for the relief of bladder outlet obstruction (eg,
transurethral resectionof theprostate)shouldnotbeconsidered in
patients whose primary complaint is nocturia, but may be an option 
insomepatientswithLUTS,bladderoutletobstructionandpostvoid
residual urine who fail medical therapy, assuming that they are good 
surgical candidates.71Acomprehensiveassessmentofthecause(s)of
nocturiashouldbeuntakeninallpatientsconsideredforsurgery.71
Nocturia often improves in patientswithOSAusing continuous
positive airway pressure.41 Patients who undergo uvulopalatopha-
ryngoplastyfortheirOSAhavealsoseenanimprovementinnocturia
symptoms.86
Recommendations on the treatment of nocturia
• Treatmentshouldbe tailored to thecause(s)ofnocturia in
the individual patient.
• Somemedications can precipitate nocturia and, therefore,
change of the drug or timing of drug use may be warranted.
• Lifestyle and behavioural modifications should be attempted 
before instigating other treatments, with a trial of up to 
3 months, a reasonable time period over which to assess 
treatment response, unless bother is increasing and 
intolerable.
• Pharmacological therapies should be introduced after life-




• Desmopressin is the pharmacologic treatment for nocturia 
duetonocturnalpolyuriawiththehighestqualityevidence
to support its use, with a once-daily, low-dose, gender-spe-
cific formulation indicated for nocturia due to nocturnal 
polyuria.
• Diuretics, α1-blockers,5α-reductaseinhibitors,PDE5i,plant
extracts,antimuscarinicsandtheβ3-agonist mirabegron all 
havepotentialutilitytoreducenocturnalvoidingfrequency
in patients with different causes of decreased functional 
bladder capacity, although the clinical impact of such treat-
ments appears to be limited.
• Educating patients on the available treatment options and
involving them in thedecision-makingprocess canhelp to
increase adherence to medication and thereby improve pa-
tientfunctioningandQoL.87
• After implementing therapy, its efficacy and effect on pa-
tients should be assessed, with consideration given to com-
biningtherapies/interventionsinthelightofaninadequate
response.
• Patients with nocturia of undetermined cause not respond-
ing to lifestyle and medical therapy should be considered for 
specialist assessment.
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4  | CONCLUSIONS
Nocturiaisahighlyprevalentseriousmedicalconditionequallyaf-
fecting men and women of all ages. It can have a profound impact 
onQoL andwork productivity and can increase the risk of falls,
fractures and mortality whilst disrupting the restorative part of 
sleep. Due to its multifactorial aetiology, nocturia should poten-
tially be viewed as a distinct medical presentation in its own right, 
albeit one that is a symptom of an underlying disease or misbehav-
iour. With appropriate assessment and diagnosis, this bothersome 
condition can be treated successfully. Use of the FVC alongside
comprehensive patient evaluation is essential to accurately iden-
tify the cause(s) behind nocturia and thereby tailor the optimal
management approach. Lifestyle modifications and behavioural 
interventions are the first step in successfully managing nocturia 
and should be discussed with every patient. When lifestyle modi-
ficationsfailoryieldaninadequateresponse,thenmedicalthera-
pies, such as desmopressin, should be introduced. Patients with 
nocturia not responding to these treatments should be referred to 
the appropriate specialist based on the underlying aetiology or to 
a specialist innocturiawhen thecause isunknown.As thereare
currently no separate guidelines on the management of nocturia 
available, this article could serve as a temporary, evidence- based 
recommendation on the assessment and treatment of nocturia 
to guide general practitioners, urologists, gynaecologists or other 
medical specialties.
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